Bayer Aktien Stock Price, News & Analysis

Monsanto (OTC:BAYRY) has announced agreements in principle to resolve PCB-related litigation cases involving over 200 plaintiffs from the Sky Valley Education Center in Washington state. The settlement excludes nine prior adverse verdicts (involving 49 plaintiffs) that remain under appeal.

The settlement costs are covered by the PCB litigation provision taken in Q2 2025. The company is pursuing a strategy to contain litigation risks by the end of 2026 and has filed a complaint in Missouri to enforce indemnity contracts signed in 1972 by former electrical manufacturing customers.

Bayer (OTC:BAYRY) has announced the U.S. launch of Aspirina, its leading pain relief product in Mexico, targeting the growing Hispanic market. The strategic expansion aims to serve the Hispanic population, which currently represents 19% of the U.S. population and is projected to reach 28% by 2060.

Aspirina holds impressive market metrics in Mexico, including a 99% awareness rate and 67% regular consumer usage. The product will be available at select Walmart and Walgreens locations, leveraging Bayer's 125-year legacy in aspirin manufacturing and the strong cultural connection among Hispanic consumers, with 70% maintaining strong ties to their country of origin.

Summary not available.

PPG (NYSE: PPG) reported record net sales of approximately $17.7 billion for 2022, marking a 5% increase from 2021, fueled by an 8% rise in organic sales due to higher prices. The company announced its 51st consecutive annual dividend hike, continuing a 123-year streak of uninterrupted payments. Key environmental achievements included a 13% reduction in greenhouse gas emissions and an investment of $16.2 million in nonprofit support, particularly in STEM education. CEO Tim Knavish expressed optimism for future growth as the economic environment improves, emphasizing cash generation and margin management. Shareholder actions included the re-election of directors and approval of executive compensation practices.

The global market for Agricultural Biotechnology is projected to grow from US$43.3 Billion in 2022 to US$88.9 Billion by 2030, reflecting a CAGR of 9.4%. The U.S. market is estimated at US$12.7 Billion, while China is expected to reach US$15.2 Billion by the same period, growing at an 8.7% CAGR. Notably, the Molecular Diagnostics segment is projected to achieve a 10.8% CAGR with an expected value of US$35.6 Billion. The report highlights significant growth in Tissue Culture at 10.1% CAGR and features key competitors including Bayer CropScience, BASF, and Syngenta. Special coverage for 2023 includes insights on the impacts of global inflation, the Russia-Ukraine conflict, and supply chain disruptions.

GreenLab, Inc. announces the appointment of Ryan Schon as the new Chief Operating Officer effective April 6, 2023. Schon will spearhead the launch of the company’s innovative GreenLab Vector Technology (GVT) platform, aimed at revolutionizing protein production in biomanufacturing.

Schon, a veteran with 25 years of experience in the seed industry, including key positions at Monsanto and Corteva, brings valuable expertise in strategy and management. His leadership is expected to enhance GreenLab's capacity to produce novel proteins while addressing crucial scalability and regulatory challenges.

The company currently has three transformative enzymes in production and is focused on commercializing the sweet recombinant protein brazzein. GreenLab aims to partner with various industries to optimize sustainable protein manufacturing.

The global Phosphoric Acid (Pharmaceutical Grade) market reached approximately 2,000,000 tonnes in 2021, with a projected growth rate of 5.16% CAGR until 2030, potentially reaching 3,000,000 tonnes. The primary driver is the Oral Care industry, utilizing phosphoric acid in dental bonding. The market is dominated by the Asia Pacific region, accounting for 45% of consumption, with China and Taiwan as key producers. The report segments the market by end-use, sales channel, and region, highlighting the significant role of phosphoric acid in dentistry and medication.

Genective, a joint venture between Limagrain and KWS, announces the appointment of Thomas Clark, Ph.D., as VP of Research and CSO, succeeding Francois Torney, Ph.D. Clark brings over 30 years of experience in agricultural product development, previously holding leadership roles at Provivi and Monsanto. His expertise is expected to strengthen Genective's capabilities in transgenic traits, particularly insect control technologies. The change in leadership is aligned with Genective's aim to enhance its research engine and meet increasing market demands sustainably.

Deiya Pernas, former Deputy Chief Investment Officer of The Bahnsen Group, has announced the launch of Pernas Research, a new stock research firm aimed at discerning investors. The firm seeks to fill a gap in quality stock research amidst a market saturated with low-quality content. Pernas Research focuses on attractively-priced companies, emphasizing those with sustainable cash flows or a path to recovery. Deiya, who helped grow The Bahnsen Group's assets from $500 million to $3.5 billion, aims to set a new standard in accessible investment research.